Month: May 2021

TORONTO, May 13, 2021 (GLOBE NEWSWIRE) — Flora Growth Corp. (NASDAQ: FLGC) (“Flora” or the “Company”), an all-outdoor cultivator and manufacturer of cannabis-derived products and brands, today announced the closing of its initial public offering of 3,333,333 of its common shares. On May 11, 2021, the Company’s common shares commenced trading on the Nasdaq Capital Market under the ticker symbol “FLGC”. The initial public offering was priced at the high end of the proposed price range at US$5.00 per share to the public for a total of US$16,666,665 of gross proceeds to the Company. Boustead Securities, LLC acted as the sole underwriter for the offering (the “Underwriter”) with MKM Partners acting as co-Manager. The Underwriter has been granted a 45-day option to purchase up to an additional 500,000 common shares to cover over-allotments...

The board of directors of IDEX Biometrics ASA resolved on 12 May 2021 to issue 999,400 incentive subscription rights to employees in the IDEX group. The grant was made under the company’s 2021 incentive subscription rights plan as resolved at the annual general meeting on 12 May 2021. The exercise price of the subscription rights is NOK 2.48 per share. The subscription rights vest by 25% per year over four years and expire on 15 May 2026. Following the grant there are 30,781,659 subscription rights outstanding in IDEX. For further information contact:Marianne Bøe, Investor Relations E-mail: marianne.boe@idexbiometrics.comTel: + 47 9180 0186 Brett L. Perry, U.S. Investor RelationsE-mail: bperry@sheltongroup.comTel: +1 214 272 0070 About IDEX BiometricsIDEX Biometrics ASA (OSE: IDEX and Nasdaq: IDBA) is a leading provider of fingerprint...

CALGARY, Alberta, May 13, 2021 (GLOBE NEWSWIRE) — Big Rock Brewery Inc. (TSX: BR) (“Big Rock” or the “Corporation“) is pleased to announce that its shareholders approved all resolutions at its annual general meeting of shareholders held today (the “Meeting”). The resolutions approved at the Meeting were as follows: The resolution to fix the number of directors of the Corporation to be elected at the Meeting at six (6) directors was approved. The resolution to appoint the six (6) nominees as directors of the Corporation to serve until the next annual meeting of shareholders of the Corporation, or until their successors are elected or appointed, was passed by way of ballot and each of the directors received the following votes for their election:Nominee   Votes For   Percent   Votes Withheld   PercentMichael Kohut   559,689   95.56%   26,006   4.44%Kathleen...

The annual general meeting of IDEX Biometrics ASA on 12 May 2020 resolved that the board members could elect to receive all or part of the board remuneration in the form of shares in IDEX. The shares are locked up for one year from the date of the annual general meeting. Three board members elected to take full or part of the board remuneration in shares, and 535,583 new shares will be issued when the share capital has been paid in. Following the issue of the new shares to the board members, the company’s share capital will be NOK 137,588,410.20 divided into 917,256,068 registered shares each with a nominal value of NOK 0.15. IDEX discloses transactions by the following primary insiders in IDEX shares ISIN NO0003070609: Board member Lawrence John Ciaccia has subscribed for 143,458 shares to replace cash board remuneration of NOK 267,500,...

– Established cGMP manufacturing and development agreement with Catalent for otoferlin dual-vector gene therapy, DB-OTO – – Successfully completed the second tranche of an oversubscribed Series D financing and upsized Initial Public Offering raising approximately $165.3M in gross proceeds – BOSTON, May 13, 2021 (GLOBE NEWSWIRE) — Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update. “The start of 2021 marked a pivotal time for Decibel as we successfully closed our upsized IPO. With this strong financial foundation, we are in a position to further advance our exciting pipeline of clinical, preclinical...

Clinical drug pipeline is funded and targeting major milestones in Q2 and 2H 2021 HANOVER, Md., May 13, 2021 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, today announces financial results for the year ended March 31, 2021, and provides corporate update. Dr. David Young, CEO and chairman of Processa, commented, “During the first quarter we made substantial progress advancing our three clinical in-licensed drugs, each with a potential market exceeding $1 billion. We expect first patients to be dosed with PCS6422 and PCS499 within the next six weeks, and to receive interim data...

First Patient Dosed in Validive® Phase 2b/3 VOICE Clinical TrialCamsirubicin Run-in Clinical Trial Now Planned to Start in 2H 2021Potential Utility Reported for MNPR-101 as Imaging Agent in Cancer Surgery WILMETTE, Ill., May 13, 2021 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced first quarter 2021 financial results and recent business updates. Recent Business Updates ValidiveMonopar’s Phase 2b/3 VOICE clinical trial of Validive (clonidine HCl mucobuccal tablet) for the prevention of severe oral mucositis (SOM) in patients undergoing chemoradiotherapy (CRT) for oropharyngeal cancer (OPC) dosed its...